{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T18:47:05Z","timestamp":1771526825216,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10157-020-02005-4","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T13:04:53Z","timestamp":1610024693000},"page":"456-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study"],"prefix":"10.1007","volume":"25","author":[{"name":"RADIANCE-CKD Study Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terumasa","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hirakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"2005_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","volume":"3","author":"H Yamamoto","year":"2017","unstructured":"Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, et al. 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ren Rep Ther. 2017;3:36.","journal-title":"Ren Rep Ther"},{"key":"2005_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-018-1648-1","volume":"23","author":"Japanese Society of Nephrology","year":"2019","unstructured":"Japanese Society of Nephrology. Essential points from Evidence-based clinical practice guidelines for chronic kidney disease 2018. Clin Exp Nephrol. 2019;23:1\u201315.","journal-title":"Clin Exp Nephrol"},{"key":"2005_CR3","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085\u201398.","journal-title":"N Engl J Med"},{"key":"2005_CR4","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019\u201332.","journal-title":"N Engl J Med"},{"key":"2005_CR5","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"TB Dr\u00fceke","year":"2006","unstructured":"Dr\u00fceke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071\u201384.","journal-title":"N Engl J Med"},{"key":"2005_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ki.2008.295","volume":"74","author":"LA Szczech","year":"2008","unstructured":"Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alfa dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791\u20138.","journal-title":"Kidney Int"},{"key":"2005_CR7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","volume":"363","author":"SD Solomon","year":"2010","unstructured":"Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146\u201355.","journal-title":"N Engl J Med"},{"key":"2005_CR8","first-page":"953","volume":"70","author":"Y Tsubakihara","year":"2011","unstructured":"Tsubakihara Y, Itami N, Uda S, Shimizu H, Naruse T, Hayashi T, et al. Maintenance of improvement in anemia with subcutaneously injected continuous erythropoiesis receptor activator in predialysis patients with chronic kidney disease, using recombinant human erythropoietin as the control. Kidney Dial. 2011;70:953\u201363 (Japanese article).","journal-title":"Kidney Dial"},{"key":"2005_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s10157-014-1023-9","volume":"19","author":"M Kuwahara","year":"2015","unstructured":"Kuwahara M, Mandai S, Kasagi Y, Kusaka K, Tanaka T, Shikuma S, et al. Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease. Clin Exp Nephrol. 2015;19:598\u2013605.","journal-title":"Clin Exp Nephrol"},{"key":"2005_CR10","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1093\/ndt\/gfq287","volume":"25","author":"A Kainz","year":"2010","unstructured":"Kainz A, Mayer B, Kramar R, Oberbauer R. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant. 2010;25:3701\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"2005_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/j.ajkd.2011.07.014","volume":"59","author":"S Fukuma","year":"2012","unstructured":"Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis. 2012;59:108\u201316.","journal-title":"Am J Kidney Dis"},{"key":"2005_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s10157-012-0659-6","volume":"17","author":"J Ishigami","year":"2013","unstructured":"Ishigami J, Onishi T, Shikuma S, Akita W, Mori Y, Asai T, et al. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study. Clin Exp Nephrol. 2013;17:106\u201314.","journal-title":"Clin Exp Nephrol"},{"key":"2005_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000358215","volume":"37","author":"M Okazaki","year":"2014","unstructured":"Okazaki M, Komatsu M, Kawaguchi H, Tsuchiya K, Nitta K. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Blood Purif. 2014;37:106\u201312.","journal-title":"Blood Purif"},{"key":"2005_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40620-014-0121-9","volume":"28","author":"R Eriguchi","year":"2015","unstructured":"Eriguchi R, Taniguchi M, Ninomiya T, Hirakata H, Fujimi S, Tsuruya K, et al. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study. J Nephrol. 2015;28:217\u201325.","journal-title":"J Nephrol"},{"key":"2005_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.ajkd.2016.05.031","volume":"68","author":"J Luo","year":"2016","unstructured":"Luo J, Jensen DE, Maroni BJ, Brunelli SM. Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients. Am J Kidney Dis. 2016;68:763\u201371.","journal-title":"Am J Kidney Dis"},{"key":"2005_CR16","doi-asserted-by":"publisher","first-page":"e0143348","DOI":"10.1371\/journal.pone.0143348","volume":"10","author":"MN Bae","year":"2015","unstructured":"Bae MN, Kim SH, Kim YO, Jin DC, Song HC, Choi EJ, et al. Association of erythropoietin-stimulating agent responsiveness with mortality in hemodialysis and peritoneal dialysis patients. PLoS ONE. 2015;10:e0143348.","journal-title":"PLoS ONE"},{"key":"2005_CR17","first-page":"343","volume":"32","author":"M\u00c1 Guerrero-Riscos","year":"2012","unstructured":"Guerrero-Riscos M\u00c1, Montes-Delgado R, Seda-Guzm\u00e1n M, Praena-Fern\u00e1ndez JM. Erythropoietin resistance and survival in non-dialysis patients with stage 4\u20135 chronic kidney disease and heart disease. Nefrologia. 2012;32:343\u201352.","journal-title":"Nefrologia"},{"key":"2005_CR18","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1093\/ndt\/gfs007","volume":"27","author":"R Minutolo","year":"2012","unstructured":"Minutolo R, Conte G, Cianciaruso B, Bellizzi V, Camocardi A, De Paola L, et al. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol Dial Transplant. 2012;27:2880\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"2005_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/nep.12842","volume":"22","author":"K Tsuruya","year":"2017","unstructured":"Tsuruya K, Uemura Y, Hirakata H, Kitazono T, Tsubakihara Y, Suzuki M, et al. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: a pooled analysis of individual patient-level data from clinical trials. Nephrology (Carlton). 2017;22:769\u201375.","journal-title":"Nephrology (Carlton)"},{"key":"2005_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1744-9987.2012.01082.x","volume":"16","author":"Y Tsubakihara","year":"2012","unstructured":"Tsubakihara Y, Gejyo F, Nishi S, Iino Y, Watanabe Y, Suzuki M, et al. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial. 2012;16:529\u201340.","journal-title":"Ther Apher Dial"},{"key":"2005_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10157-018-1632-9","volume":"23","author":"T Tanaka","year":"2019","unstructured":"Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M, et al. Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan. Clin Exp Nephrol. 2019;23:231\u201343.","journal-title":"Clin Exp Nephrol"},{"key":"2005_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10157-018-1649-0","volume":"23","author":"T Hayashi","year":"2019","unstructured":"Hayashi T, Uemura Y, Kumagai M, Kimpara M, Kanno H, Ohashi Y, MIRACLE-CKD Study Group. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study). Clin Exp Nephrol. 2019;23:349\u201361.","journal-title":"Clin Exp Nephrol"},{"key":"2005_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.kint.2016.09.015","volume":"91","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91:227\u201334.","journal-title":"Kidney Int"},{"key":"2005_CR24","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2215\/CJN.04260415","volume":"10","author":"M Denker","year":"2015","unstructured":"Denker M, Boyle S, Anderson AH, Appel LJ, Chen J, Fink JC, et al. Chronic renal insufficiency cohort study (CRIC): overview and summary of selected findings. Clin J Am Soc Nephrol. 2015;10:2073\u201383.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2005_CR25","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1096\/fj.14-259085","volume":"29","author":"S Hiram-Bab","year":"2015","unstructured":"Hiram-Bab S, Liron T, Deshet-Unger N, Mittelman M, Gassmann M, Rauner M, et al. Erythropoietin directly stimulates osteoclast precursors and induces bone loss. FASEB J. 2015;29:1890\u2013900.","journal-title":"FASEB J"},{"key":"2005_CR26","doi-asserted-by":"publisher","first-page":"e10853","DOI":"10.1371\/journal.pone.0010853","volume":"5","author":"Y Shiozawa","year":"2010","unstructured":"Shiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z, et al. Erythropoietin couples hematopoiesis with bone formation. PLoS ONE. 2010;5:e10853.","journal-title":"PLoS ONE"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-02005-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-020-02005-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-02005-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T08:11:15Z","timestamp":1618128675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-020-02005-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2005"],"URL":"https:\/\/doi.org\/10.1007\/s10157-020-02005-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"15 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K. Tsuruya has received speakers fee as honoraria and grants from Chugai and Kyowa Kirin. T. Hayashi has received speakers fee as honoraria from Chugai and Kyowa Kirin. H. Yamamoto has received speakers fee as honoraria from Chugai and Kyowa Kirin. H. Hase has received grants from Chugai and Kyowa Kirin. S. Nishi has received speakers fee as honoraria and grants from Chugai and Kyowa Kirin. K. Yamagata has received speakers fee as honoraria and grants from Chugai and Kyowa Kirin. M. Nangaku has received speakers fee as honoraria from Chugai, Kyowa Kirin and Kissei, grants from Chugai and Kyowa Kirin, research funding from Kyowa Kirin and manuscript fee from Kyowa Kirin. T. Wada has received grants from Chugai and Kyowa Kirin, and research funding from Kyowa Kirin. Y. Uemura has received speakers fee as honoraria from Chugai. Y. Ohashi has received speakers fee as honoraria from Chugai. H. Hirakata has speakers fee as honoraria from Chugai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki and \u201cEthical Guidelines for Clinical Studies\u201d by the Ministry of Health, Labour and Welfare and in accordance with International Council for Harmonization Good Clinical Practice (ICH-GCP) guidelines. The study was approved by an independent central ethics committee and was registered in the University Hospital Medical Information Network (UMIN) database (UMIN000008617). Study treatments performed were covered by ordinary health insurance. This report was prepared according to the Consolidated Standards of Reporting Trials (CONSORT).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Written informed consent was obtained from all included participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}